Cardiovascular disease and hypertensive cardiomiopathy. Beyond heart;Enfermedad cardiovascular y cardiopatía hipertensiva. Más allá del corazón

Medicina Clinica

Volumn 126, Issue 3, 2006, Pages 99-100

  González Juanatey, José R ^a,c   Conthe, Pedro ^b  

^a University Hospital of Santiago de Compostela   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; LOSARTAN; THIAZIDE DIURETIC AGENT;

CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; EDITORIAL; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; HYPERTENSIVE HEART DISEASE; INCIDENCE; ISCHEMIC HEART DISEASE; PATHOGENESIS;

EID: 33644553839     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13083889     Document Type: Editorial

References (14)

1. Banegas JR, Rodriguez F, De la Cruz JJ, De Andrés B, Del Rey J. Mortalidad relacionada con la hipertensión y la presión arterial en España. Med Clin (Barc). 1999;112:489-94.
2. González-Juanatey JR, Mazón P, Soria F, Barrios V, Rodríguez Padial L, Bertomeu V. Actualización (2003) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en hipertensión arterial. Rev Esp Cardiol. 2003;56:487-97.
3. Dunn FG, Pfeffer MA. Left ventricular hypertrophy in hypertension. N Engl J Med. 1999;340:1279-83.
4. Mosterd A, D'Agostino RB, Silbershatz H, Sytkowski PA, Kannel WB, Grobbee DE, et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med. 1999;340:1221-7.
5. Klapholz M, Maurer M, Lowe AM, Messineo F, Meisner JS, Mitchell J, et al. New York Heart Failure Consortium. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol. 2004;43:1432-8.
6. Querejeta R, López B, González A, Sánchez E, Larman M, Martínez Ubago JL, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004;110:1263-8.
7. González A, Fortuno MA, Querejeta R, Ravassa S, López B, López N, et al. Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc Res. 2003;59:549-62.
8. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001;104:2039-44.
9. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:705-11.
10. García-Acuna JM, González-Juanatey JR, Alegría Ezquerra E, González Maqueda I, Listerri JL. Fibrilación auricular crónica en las cardiopatías en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol. 2002;55:943-52.
11. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003;41:218-23.
12. Almendral Garrote J, Marín Huerta E, Medina Moreno O, Peinado Peinado R, Pérez Álvarez L, Ruiz Granell R, et al. Guias de práctica clínica de la Sociedad Española de Cardiología en arritmias cardíacas. Rev Esp Cardiol. 2001;54:307-67.
13. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:705-11.
14. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-9.